Marianne Dicander Alexandersson
Chairman since 2022 and Board Member since 2017
Born: 1959.
Marianne has previously been CEO of Kronans Droghandel AB, Sjätte AP-fonden and Global Health Partner AB and Deputy CEO of Apoteket AB. She has a master’s degree in chemical engineering from Chalmers University of Technology in Gothenburg.
Other assignments: Marianne is chairman of the board of Sahlgrenska Science Park AB, Saminvest AB and Occlutech Holding AG. She is a board member of Oblique AB and Linc AB. She is a board member and CEO of MDA Management AB.
Independent in relation to Promore Pharma and its senior executives: Yes.
Independent in relation to major shareholders: Yes.
Holding in Promore Pharma: No current holding.
Born: 1959.
Marianne has previously been CEO of Kronans Droghandel AB, Sjätte AP-fonden and Global Health Partner AB and Deputy CEO of Apoteket AB. She has a master’s degree in chemical engineering from Chalmers University of Technology in Gothenburg.
Other assignments: Marianne is chairman of the board of Sahlgrenska Science Park AB, Saminvest AB and Occlutech Holding AG. She is a board member of Oblique AB and Linc AB. She is a board member and CEO of MDA Management AB.
Independent in relation to Promore Pharma and its senior executives: Yes.
Independent in relation to major shareholders: Yes.
Holding in Promore Pharma: No current holding.
Göran Linder
Board Member since 2015
Born: 1962.
Göran is a senior executive in several investment companies. Göran has a master’s degree in electronics from the Royal Institute of Technology in Stockholm.
Other assignments: CEO and board member of Granitor Growth Management AB, Corespring Invest AB, Corespring New Technology AB, Corespring Finance AB. Chairman of Crunchfish AB (publ) and QCG Sweden AB. Board member of Minesto AB (publ), Minesto Warrants One AB, Powercell Warrants One AB, Pergamum AB, Pergasus AB, Checkproof AB, as well as EffRx Pharmaceuticals SA, board deputy of Corpower Ocean AB.
Independent in relation to Promore Pharma and its senior executives: Yes.
Independent in relation to major shareholders: No.
Holding in Promore Pharma: Represents Corespring New Technology AB which owns 22,710,730 shares in the company.
Born: 1962.
Göran is a senior executive in several investment companies. Göran has a master’s degree in electronics from the Royal Institute of Technology in Stockholm.
Other assignments: CEO and board member of Granitor Growth Management AB, Corespring Invest AB, Corespring New Technology AB, Corespring Finance AB. Chairman of Crunchfish AB (publ) and QCG Sweden AB. Board member of Minesto AB (publ), Minesto Warrants One AB, Powercell Warrants One AB, Pergamum AB, Pergasus AB, Checkproof AB, as well as EffRx Pharmaceuticals SA, board deputy of Corpower Ocean AB.
Independent in relation to Promore Pharma and its senior executives: Yes.
Independent in relation to major shareholders: No.
Holding in Promore Pharma: Represents Corespring New Technology AB which owns 22,710,730 shares in the company.
Kerstin Valinder Strinnholm
Board Member since 2019
Born: 1960.
Kerstin has been responsible for business development and business strategy at Nycomed (now Takeda) and previously held leading positions in marketing and business development at Astra and AstraZeneca. She has a degree from the journalism program at the University of Gothenburg.
Other assignments: Chairman of Moberg Pharma AB, Board member of Immedica Pharma AB, Camurus AB, KVS Invest AB, Cavastor AB, and Bioservo Technologies AB.
Independent in relation to Promore Pharma and its senior executives: Yes.
Independent in relation to major shareholders: Yes.
Holding in Promore Pharma: No current holding.
Born: 1960.
Kerstin has been responsible for business development and business strategy at Nycomed (now Takeda) and previously held leading positions in marketing and business development at Astra and AstraZeneca. She has a degree from the journalism program at the University of Gothenburg.
Other assignments: Chairman of Moberg Pharma AB, Board member of Immedica Pharma AB, Camurus AB, KVS Invest AB, Cavastor AB, and Bioservo Technologies AB.
Independent in relation to Promore Pharma and its senior executives: Yes.
Independent in relation to major shareholders: Yes.
Holding in Promore Pharma: No current holding.
Hans-Peter Ostler
Board Member since 2021
Born: 1971.
Hans-Peter Ostler possesses close to three decades of experience in investment banking and private banking.
Other assignments: Hans-Peter Ostler is Chairman of the Board in Ectin Research AB and Improve Tec Hönö AB, vice chairman in Alligator Biosciences AB, board member of RGNT Electric AB, Hoodin AB, InorbitTX, Oblique Therapeutics AB and Lennart Ekerholms Stiftelse. Deputy board member in O Mgmt AB. Independent in relation to Promore Pharma and its senior executives: Yes.
Independent in relation to major shareholders: Yes.
Holding in Promore Pharma: 646,010 shares.
Born: 1971.
Hans-Peter Ostler possesses close to three decades of experience in investment banking and private banking.
Other assignments: Hans-Peter Ostler is Chairman of the Board in Ectin Research AB and Improve Tec Hönö AB, vice chairman in Alligator Biosciences AB, board member of RGNT Electric AB, Hoodin AB, InorbitTX, Oblique Therapeutics AB and Lennart Ekerholms Stiftelse. Deputy board member in O Mgmt AB. Independent in relation to Promore Pharma and its senior executives: Yes.
Independent in relation to major shareholders: Yes.
Holding in Promore Pharma: 646,010 shares.
Candice (Yujin) Jung
Board member since 2022
Born: 1991.
Candice serves as head of PharmaResearch USA. She has a Doctor of Pharmacy (PharmD) degree from Northeastern University, Boston, USA. She has previously held positions in marketing and business development including within Johnson & Johnson and the South Korean pharmaceutical company Daewoong Pharmaceutical.
Other assignments: Candice holds no other board assignments.
Independent in relation to Promore Pharma and its senior executives: Yes.
Independent in relation to major shareholders: No.
Holding in Promore Pharma: Representing PharmaResearch Co. Ltd and PharmaResearch USA owning 7,468,132 shares in the Company.
Holdings as of May 23, 2023.